A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Berenson, James R.
Klein, Leonard M.
Rosen, Peter J.
Woliver, Thomas B. S.
Eshaghlan, Shahrooz
Nassir, Youram
Swift, Regina A.
Vescio, Robert A.
机构：
[1] James R Berenson MD Inc, West Hollywood, CA USA
[2] Illinois Canc Specialists, Niles, IL USA
[3] Providence St Joseph Med Ctr, Burbank, CA USA
[4] Canc Ctr Santa Barbara, Santa Barbara, CA USA
[5] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[6] Canc Care Inst, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19586
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
    Berenson, James R.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter
    Klein, Leonard M.
    Woliver, Thomas B. S.
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Berenson, James
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Regina, Swift A.
    James, Wang
    Benjamin, Eades
    Spektor, Tanya M.
    Vescio, Robert
    [J]. BLOOD, 2015, 126 (23)
  • [3] A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Hilger, James D.
    Klein, Leonard M.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    [J]. BLOOD, 2012, 120 (21)
  • [4] A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM)
    Hilger, James D.
    Berenson, James R.
    Klein, Leonard M.
    Bessudo, Alberto
    Rosen, Peter J.
    Eshaghian, Shahrooz
    Chamras, Hilda
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    [J]. HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [6] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    [J]. BLOOD, 2014, 124 (21)
  • [7] Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
    Cohen, Alexa
    Spektor, Tanya M.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall
    Eshaghian, Shahrooz
    Nassir, Youram
    Maluso, Tina
    Swift, Regina A.
    Vescio, Robert
    Berenson, James R.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 60 - 70
  • [8] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Kanagavel, Dheepak
    Gao, Lei
    Ziti-Ljajic, Samira
    Anderson, Kenneth C.
    [J]. BLOOD, 2017, 130
  • [9] Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)
    Richardson, Paul
    Mikhael, Joseph
    Usmani, Saad
    Raje, Napoor
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E17
  • [10] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
    Mikhael, Joseph
    Richardson, Paul G.
    Usmani, Saad Zafar
    Raje, Noopur S.
    Bensinger, William
    Dubin, Franck
    Liu, Qianying
    Vitse, Olivier
    Anderson, Kenneth Carl
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345